1. Introduction {#sec0001}
===============

Photophobia is a common and debilitating symptom that describes painful sensitivity to light. It is often associated with migraine and other neurological disorders, but can also arise from ocular pathologies, psychiatric conditions, and as a pharmacological side effect ([@bib0001], [@bib0011], [@bib0019]). Despite its common prevalence, photophobia remains poorly understood. This is perhaps due to the wide variety of pathologies that can cause this symptom.

Even when considering only light transduction in the eye, photophobia may be triggered through melanopsin pathways (non-image forming), rod and cone pathways (image-forming), or through some combination of the two. At least three melanopsin pathways have been proposed for primates and non-primate mammals: (1) in the retina, intrinsic photosensitive retinal ganglion cells (ipRGCs) containing melanopsin photopigment activate nociceptive trigeminovascular thalamic neurons ([@bib0020]); (2) in the iris ([@bib0034]), melanopsin-containing nociceptive-afferents are activated by light ([@bib0006]); and (3) in the cornea, melanopsin is expressed on and directly activates trigeminovascular afferents ([@bib0015]), which may be sensitized by ocular surface injury ([@bib0016]). With traditional retinal light transduction pathways, photophobia has been proposed to act through (1) rods and cones parasympathetically triggering ocular vasodilation, which in turn activate trigeminal nociceptive afferents in blood vessels, ([@bib0021]) or (2) cone pathways relaying light signals to nociceptive trigeminovascular thalamic neurons ([@bib0020]). The common theme is the intersection of afferent visual processing with nociceptive trigeminal pathways ([@bib0011], [@bib0019], [@bib0024]).

We evaluated a patient who suffered from longstanding idiopathic photophobia with no diagnosis of migraine. The patient reported that her longstanding painful sensitivity to light was markedly reduced when she wore FL-41 tinted lenses (TheraSpecs Co., Phoenix, AZ). The FL-41 tint maximally filters wavelengths of light within the spectral sensitivity of melanopsin, around 480 nm. This case study provided an opportunity to identify the neural circuitry underlying photophobia that is presumably mediated by melanopsin.

We hypothesized that with the presentation of blue light to this patient, we would evoke photophobia and see functional magnetic resonance imaging (fMRI) activation of nociceptive trigeminal pathways.

1.1. Case report {#sec0002}
----------------

A 39-year-old Caucasian female presented with longstanding idiopathic photophobia. She reported that exposure to blue light produced constant eye pain and that her vision would become blurry, as if there were "like talcum powder sprinkled in the air." She also reported contraction of muscles in her face, nausea, increased heart rate, strong negative affect, and a "strong sense of fear and isolation." She indicated that she has had these symptoms for as long as she can remember, and did not report any similar history of photophobia in family members.

The subject had managed her photophobia using Theraspecs FL-41 tinted lenses for the past three years. She reported that when she first wore these lenses, her lifelong anxiety related to photophobia "decreased dramatically within 2 days." She noted that the therapeutic effect was instantaneous when she wore them. She reported no major sleep/wake cycle issues, though she occasionally took sedatives as a sleep aid.

Her medical history was positive for myofascial pain syndrome, fibromyalgia, Asperger\'s Syndrome, congenital heart defects, and polycystic ovarian syndrome. Aside from photophobia, she reported no symptoms consistent with migraine, and had not been diagnosed with migraine. She had previously received a CT scan and a 17-channel EEG (Baton Rouge Clinic 2012), both diagnosed as normal. For medications, she reported taking Niacin (500 mg), and low-dose Naltrexone (4.5 mg) for her fibromyalgia.

Her previous eye exams (in 2012, 2014, and 2016) revealed no pathology of the cornea or retina, despite photophobia being reported as the chief complaint. These exams were each performed by independent ophthalmologists. Optical coherence tomography (OCT, 2014) were reported as normal and revealed no ocular pathology or signs of retinal dystrophy. Her electroretinogram records (ERG, 2014) indicated normal inner and outer retinal responses (a- and b-wave amplitudes, latency, and shape) under dark-adapted rod-only conditions, normal responses in dark-adapted bright flash test conditions, normal responses in light-adapted conditions, and normal amplitudes and latencies with 30 Hz flicker testing. Fluorescein angiography (2012) showed normal vascular fill time with no leakage or ischemia.

2. Methods {#sec0003}
==========

This study was approved by the McLean Hospital Institutional Review Board, and met the scientific and ethical guidelines for human research of the Helsinki Accord (<http://ohsr.od.nih.gov/guidelines/helsinki.html>). The subject provided written informed consent to participate in this study.

The subject participated in a 1-hour session during which she was presented with visual stimuli in an event-related fMRI experiment. During fMRI scanning, the subject used a prism mirror to view a presentation projected on a screen just outside of the scanner bore. The stimuli were presented on a screen subtending 17 × 12° of visual angle by a Cannon WUX 500 projector. The stimuli were presented bilaterally, as the patient viewed them binocularly.

2.1. Stimulation protocol {#sec0004}
-------------------------

The protocol consisted of a bilateral stimulus that triggered the patient\'s symptoms (SYMPT), a stimulus that did not elicit any symptoms (ASYMPT), and a baseline that featured a black screen with a fixation cross. The SYMPT and ASYMPT stimuli were checkerboards with squares that each subtended 0.5° of visual angle, reversing at 7 Hz. The SYMPT stimulus consisted of white and blue checks with \~80% luminance contrast, of which the blue checks were generated using only the blue LED of the projector. The ASYMPT stimulus consisted of white and red checks with \~80% luminance contrast, of which the red checks were generated using only the red LED of the projector. The difference in melanopsin activation between the SYMPT and ASYMPT conditions was \~78%, with the SYMPT condition eliciting the greater melanopsin response. The subject stayed awake and attentive throughout the scan, confirmed by close observation and also quantitatively by noting no motion artifacts in the fMRI data that normally accompany changes in consciousness.

Each checkerboard stimulus was presented in 6-second blocks, with nine SYMPT and nine ASYMPT blocks presented in pseudorandom order. To avoid anticipatory processes, the inter-stimulus interval (ISI) was varied between 51 s and 66 s in 3-second increments, to match the fMRI acquisition. The total duration of the fMRI stimulus paradigm was 19 min 30 s. The scanner environment was kept dark during the entire experiment, with only the projector providing intermittent brief illumination. At the end of the session, the subject retrospectively rated light-evoked pain intensity and unpleasantness on a numerical rating scale (0--10). The extremes of the pain intensity scale were marked "None" and "Most intense pain imaginable", and the extremes for the unpleasantness scale were marked "None" and "Most unpleasant imaginable."

2.2. fMRI imaging {#sec0005}
-----------------

Imaging was conducted using a 3T Siemens Trio scanner (Erlangen, Germany) with a phased-array head coil. For anatomical scans, a sagittal three-dimensional T1-weighted scan (MPRAGE) was performed (TE/TR = 2.74/2100 msec; field of view = 256 mm^2^; slice thickness = contiguous 1.33 mm; in-plane resolution = 1.00 mm). For the functional scan, a gradient echo (GE) echo planar imaging (EPI) sequence was performed (TE/TR = 30/2000 ms; field of view = 264 mm^2^; slice thickness = contiguous 1.50 mm; in-plane resolution = 1.94 mm), with 585 vol (19 min 30 s) captured. The functional scan consisted of 84 slices oriented in an oblique plane, to match the brainstem axis. This orientation of acquisition has proven useful for functional imaging of brainstem structures ([@bib0016]).

2.3. Data analysis {#sec0006}
------------------

Functional imaging datasets were processed and analyzed using FEAT (FMRI Expert Analysis Tool) Version 6.00, part of FSL 5.0.0 (FMRIB\'s Software Library, [www.fmrib.ox.ac.uk/fsl](http://www.fmrib.ox.ac.uk/fsl){#interref0003}) ([@bib0028]). Pre-processing included elimination of the first four acquired volumes to allow for signal equilibration; motion correction using MCFLIRT (Motion Correction using FMRIB\'s Linear Image Registration Tool) ([@bib0009]); removal of non-brain structures using BET \[Brain Extraction Tool\] ([@bib0027]); spatial smoothing using a Gaussian kernel of 5-mm full-width half-maximum; grand-mean intensity normalization of the entire 4D dataset by a single multiplicative factor; and high-pass temporal filtering (Gaussian-weighted least-squares straight line fitting with sigma = 50.0 s). Fixed effects time-series analysis using the general linear model was implemented with FILM (FMRIB\'s Improved Linear Model) with local autocorrelation correction ([@bib0032]). The hemodynamic response was modeled using a gamma convolution (SD = 3 s; mean lag = 6 s) of the checkerboard stimulation block, which included three volumes during the stimulus. Each activation map (SYMPT and ASYMPT) thus reflects a comparison of nine stimulus events (totaling 27 vol) vs. 527 vol of baseline. A contrast was included between the SYMPT (blue photophobic state) and ASYMPT (red non-photophobic state) explanatory variables. The statistical parametric maps for each session and contrast maps were co-registered to the high-resolution anatomical scan using FLIRT (FMRIB\'s Linear Image Registration Tool) ([@bib0010]). Registration to Montreal Neurological Institute (MNI) standard space was achieved using Advanced Normalization Tools 2.3.1 ([@bib0004]). Z-statistic images were thresholded using clusters determined by *Z* \> 3.1 and a (corrected) cluster significance threshold of *P* = *0.05* ([@bib0033]).

3. Results {#sec0007}
==========

The subject rated the SYMPT blue stimulus as 2/10 for pain intensity and 6/10 for unpleasantness; she rated the ASYMPT red stimulus as 0/10 for pain intensity and 0/10 for unpleasantness. She reported that the SYMPT stimulus onset immediately produced a painful, unpleasant sensation and general feeling of malaise, which would cease the moment the stimulus ended.

Both SYMPT and ASYMPT conditions produced robust cortical activation, particularly in visual cortices ([Fig. 1](#fig0001){ref-type="fig"}, [Table 1](#tbl0001){ref-type="table"}, [Table 2](#tbl0002){ref-type="table"}). Activation in bilateral pulvinar nuclei was significantly greater with SYMPT than ASYMPT stimulation ([Fig. 1](#fig0001){ref-type="fig"}, [Table 3](#tbl0003){ref-type="table"}). Other areas with significantly greater activation under SYMPT conditions included right inferior frontal gyrus, right occipital fusiform gyrus, right cerebellar crus II, left frontal orbital cortex, and left brainstem ([Table 3](#tbl0003){ref-type="table"}). No areas showed significantly greater activation with ASYMPT visual stimulation.Fig. 1Pulvinar nuclei, anterior insula, cerebellar crus II, and inferior frontal gyrus are significantly more activated with the photophobia-evoking stimulus (SYMPT) than the control (ASYMPT). Visual cortex and other brain areas were significantly activated in response to the SYMPT condition and the ASYMPT condition. The green represents areas that showed a significant contrast in SYMPT\>ASYMPT. No regions were found where a significant contrast was found in ASYMPT\>SYMPT. The images are displayed in the patient\'s native high-resolution space to avoid potential artifacts from spatial transformation to a standard brain atlas. Significant activations and contrasts were thresholded using clusters determined by *Z* \> 3.1 and a (corrected) cluster significance threshold of *P* = *0.05. A*=anterior, BS=brainstem, IFG=inferior frontal gyrus, *L*=left, *P*=posterior, *R*=right.Fig. 1Table 1SYMPT Activation.Table 1Brain RegionSideMNI[\*](#tb1fn1){ref-type="table-fn"}Max Z-statIntracalcarineB−9,−87,−19.62Middle Frontal GyrusR40,25,208.64Paracingulate GyrusR4,9,527.08B0,24,425.23Thalamus (Pulvinar)R10,−29,−16.19Lateral OccipitalL−35,−61,586.13Cerebellum VIIbL−6,−76,−446.12R31,−69,−525.42ThalamusR13,−3,146.07L−12,−20,−14.44L−25,−32,−14.03L−4,−13,−23.98Cerebellar Crus IIL−39,−43,−445.91Cerebellum VIIIaR32,−42,−475.55Supramarginal GyrusR60,−23,365.06Frontal PoleR36,39,395.4L−32,47,354.86R8,62,344.41Precentral GyrusL−59,3,135.27R41,−11,465.01Cerebellar Vermis IXB0,−53,−375.18PutamenR29,10,−54.89L−22,4,44.83R31,0,54.18CaudateL−12,4,204.80R11,8,44.28L−17,−16,203.79Inferior Frontal GyrusR56,20,64.72R43,33,54.23Occipital PoleB2,−100,−94.56R9,−88,364.04Postcentral GyrusL−66,−21,254.36R54,−17,254.23Parahippocampal GyrusR23,−30,−224.41Frontal OperculumR37,12,124.21InsulaL−44,12,−54.13R33,−14,153.91Superior Parietal LobuleR28,−49,403.94CunealB0,−78,293.84[^2]Table 2ASYMPT Activation.Table 2Brain RegionSideMNI[\*](#tb2fn1){ref-type="table-fn"}Max Z-statLingualB−1,−81,−210.2Frontal OrbitalR33,29,−276.16R23,6,−194.69PrecuneousR16,−36,465.71L−12,−65,394.71Superior Temporal GyrusL−66,−14,15.68Cerebellum Vermis IXB0,−55,−365.67Precentral GyrusL−42,−3,385.65Planum PolareL−41,−11,−155.30Supramarginal GyrusL−66,−23,315.19R65,−31,353.51Paracingulate GyrusR11,37,225.18Juxtapositional LobuleR11,3,535.14Temporal FusiformR34,−34,−275.12Inferior Temporal GyrusR61,−36,−175.03Cingulate, PosteriorB−2,−22,305.01Central OpercularR41,11,55.01AmygdalaR14,−1,−154.94Superior Parietal LobuleL−38,−56,524.88R29,−42,414.87L−26,−49,434.18Cerebellar Lobule VIL−30,−34,−404.82Parahippocampal GyrusL−24,0,−384.66R18,−7,−354.56BrainstemR9,−27,−134.63B0,−38,−124.44R14,−23,−334.38B−2,−32,−394.34R7,−39,−384.28Cingulate, AnteriorL−8,17,304.59B8,−6,344.31Frontal PoleR−43,53,174.54L−49,48,−74.50R53,41,44.31L−21,44,−184.29R33,44,−164.18R16,63,−184.08R20,69,−64.03Lateral OccipitalR35,−68,254.54L−20,−74,544.53Middle Frontal GyrusL−29,−4,584.46Cerebellar VIIIaR37,−48,−514.37Cerebellum (Dentate)L−22,−52,−394.29PutamenR31,−6,94.28InsulaL−38,1,64.19L−34,13,63.78Thalamus (Pulvinar)L−19,−31,134.13Middle Temporal GyrusR54,−2,−353.92[^3]Table 3SYMPT\>ASYMPT Contrast.Table 3Brain RegionSideMNI[\*](#tb3fn1){ref-type="table-fn"}Max Z-statThalamus (Pulvinar)B10,−31,04.86Inferior Frontal GyrusR41,23,204.61Occipital Fusiform GyrusR38,−68,−174.34Cerebellar Crus IIR33,−81,−433.92R33,−63,−453.64R25,−75,−403.55Frontal Orbital / Anterior InsulaL−44,22,−93.87BrainstemL−9,−36,−493.83[^4]

The trigeminal nociceptive pathway was sparsely activated with both stimuli ([Table 1](#tbl0001){ref-type="table"}), but no significant differences were detected between the two conditions. In this pathway, SYMPT only showed activation in bilateral ventroposteromedial thalamic nuclei, with no activation in the spinal trigeminal nuclei or trigeminal ganglia. ASYMPT showed activation in the brainstem near the vicinity of bilateral spinal trigeminal nuclei but no activation in ventroposteriomedial thalamic nuclei or trigeminal ganglia.

4. Discussion {#sec0008}
=============

In a patient with longstanding idiopathic photophobia, symptomatic vs. asymptomatic visual stimuli produced significantly greater activation in bilateral pulvinar nuclei. These thalamic nuclei are associated with the melanopsin ipRGC visual pathway ([@bib0002]; [@bib0013]), and their activation is consistent with the patient\'s report that blue light differentially evoked photophobia. This appears to be the first demonstration of functional activation of the ipRGC pathway during photophobia in a patient.

4.1. Melanopsin {#sec0009}
---------------

Several lines of evidence support the involvement of a melanopsin pathway with photophobia in this patient: (1) her report that cool blue light triggered her photophobia; (2) the fact that FL-41 tinted lenses, which filter melanopsin-related wavelengths of light, helped manage her photophobia; (3) the pulvinar nuclei, which have been previously structurally associated with the ipRGC pathway ([@bib0002]; [@bib0013]), were significantly activated by the blue visual stimuli that triggered photophobia; and (4) pulvinar nuclei activation has previously been related to migraine-related allodynia, which describes painful sensitivity to stimuli that is normally non-noxious ([@bib0005]).

In healthy subjects without photophobia, melanopic signals have previously been shown to elicit fMRI responses in the bilateral frontal eye fields, inferior temporal gyri, caudate nuclei ([@bib0008]), as well as primary visual cortex ([@bib0029]). The lack of pulvinar activation in these healthy subjects in response to melanopic signals is consistent with our suggestion that this differential pulvinar activation represents a pathological process related to our patient\'s photophobia.

Considered together, these fMRI results suggest a sensitization of the ipRGC pathway beyond the retina. This hypothesis should be explored further in future studies that employ a larger patient cohort with greater statistical power, particularly when considering functional neuroimaging.

4.2. Trigeminal nociceptive pathway? {#sec0010}
------------------------------------

The photophobia responses observed in this patient are markedly different from our previous fMRI report of photophobia related to a corneal mechanism. Photophobia involving superficial corneal injury in a separate case study has previously been related to the trigeminal nociceptive pathway ([@bib0016]; [@bib0017]). Activation had been observed in the trigeminal ganglion ipsilateral to the injury, bilateral spinal trigeminal nuclei, contralateral ventroposteriomedial thalamus, and contralateral primary somatosensory cortex. After the photophobia had resolved, 9 days after the initial scan, these structures were no longer activated by the same visual stimulus protocol. In that study, photophobia was postulated to impact corneal sensory processing by sensitizing mechano-sensitive primary nociceptive afferents. Alternatively, recent findings that melanopsin is expressed in corneal afferents ([@bib0015]) suggest that corneal injury may impact this non-image--forming light transduction pathway, thereby leading to photophobia. Conceivably, photophobia could result from activation of melanopsin-containing afferents in the cornea that cascade into the trigeminal nociceptive pathway.

Based on activation of the pulvinar nuclei in the present study, the melanopsin route in the patient appears to start with ipRGCs at the level of the retina. A direct path from the optic nerve at the level of the optic chiasm to the pulvinar nuclei has been demonstrated in humans using diffusion tensor imaging ([@bib0013]). Though melanopsin is also expressed on afferents in the iris ([@bib0006]; [@bib0034]) and cornea ([@bib0015]), no activation of trigeminal nociceptive afferents was detected at the level of the trigeminal ganglion. Furthermore, no significant differences were detected between SYMPT and ASYMPT stimuli in any of the other structures in the trigeminal nociceptive pathway.

4.3. Beyond visual pathways {#sec0011}
---------------------------

Several brain regions outside of traditional visual pathways were also found to be more active in the SYMPT vs. ASYMPT conditions. These may represent further downstream interpretive or reactive processes related to the stimulus induction of photophobia. For example, the anterior insula is related to affective pain processing ([@bib0003]; [@bib0023]) and autonomic homeostasis, such as cardiovascular regulation ([@bib0022]). The posterior lobe of the cerebellum, including Crus II, is related to generalized aversive processing ([@bib0018]) as well as the modulation of pain affect ([@bib0026]). In the prefrontal cortex, the inferior frontal gyrus is associated with cognitive reappraisal of painful experiences ([@bib0012]). These regions and functions are consistent with the patient\'s report of photophobia.

4.4. Caveats {#sec0012}
------------

While our patient has been described as having longstanding idiopathic photophobia, several other factors may contribute to her symptoms, such as fibromyalgia. Clinical studies of fibromyalgia indicate that 70%--83% of patients exhibit photophobia ([@bib0007]; [@bib0031]). Furthermore, fibromyalgia has a 55%--63% comorbidity with migraine ([@bib0014]; [@bib0030]), which has photophobia as a defining characteristic. Though the patient reported no clinical diagnosis of migraine, a subclinical variant may have been present. Visual stimuli presented to chronic migraine patients has also been found to activate the trigeminal spinal nuclei ([@bib0025]), although the description of the stimulus parameters lack detail. Other caveats relating to our specific study include the absence of controls for blurred vision, tachycardia, facial muscle contraction, nausea, and negative affect. Regardless of specific pathological etiology, this case report demonstrates activation of a known ipRGC thalamic relay in a patient with photophobia.

5. Conclusions {#sec0013}
==============

These findings and our previous photophobia case report ([@bib0016]) support the theory that photophobia has at least two non-mutually exclusive pathways for its expression in patients: (1) through the ipRGC-optic nerve-pulvinar nuclei and (2) through the trigeminal nociceptive pathway by way of mechanical irritation and/or melanopsin stimulation of sensitized corneal afferents. While suggestive, these single-subject reports make a case for more systematic neuroimaging investigations to improve the diagnostic value of these findings. A larger cohort fMRI study with an appropriate control group would more definitively determine whether this ipRGC-pulvinar pathway is specific for this type of photophobia or whether the blue vs. red light paradigm preferentially activates this pathway in all subjects. The identification and classification of different mechanisms of photophobia may help with the diagnosis and treatment of underlying pathological conditions.
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[^2]: MNI = Montreal Neurological Institute standard space.
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